Is Inotuzumab Ozogamicin chemotherapy?

Is Inotuzumab Ozogamicin chemotherapy?

Drug Type: Inotuzumab ozogamicin is a monoclonal antibody combined with an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “Anti-CD22 monoclonal antibody and antineoplastic agent.” (For more detail, see “How Inotuzumab Ozogamicin Works” below).

What is Inotuzumab Ozogamicin used for?

Inotuzumab ozogamicin (Besponsa) Inotuzumab ozogamicin is a type of targeted cancer drug. It is a treatment for a type of acute lymphoblastic leukaemia (ALL) called B cell precursor ALL. You might have it if the leukaemia has come back (relapsed) or not responded to treatment (refractory).

Is Inotuzumab a chemotherapy?

Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them.

Is Inotuzumab Ozogamicin approved by FDA?

The Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa®) for some adults with B-cell acute lymphoblastic leukemia (ALL).

How much does Inotuzumab cost?

Pfizer’s Besponsa, or inotuzumab ozogamicin, was approved by the FDA as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. The drug will be priced at $168,300 for a typical course of treatment.

What is Ozogamicin?

Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin.

Who makes Inotuzumab?

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

How much does Besponsa cost?